1. Academic Validation
  2. Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury

Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury

  • Int Immunopharmacol. 2023 Jun 9;121:110452. doi: 10.1016/j.intimp.2023.110452.
Yanmeizhi Wu 1 Jingjing Li 1 Xu Yang 1 Boyu Hou 1 Hong Qiao 2
Affiliations

Affiliations

  • 1 Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, PR China.
  • 2 Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, PR China; NHC Key Laboratory of Etiology and Epidemiology, Harbin Medical University, Harbin 150081, PR China. Electronic address: [email protected].
Abstract

Background: Immune checkpoint inhibitors evoke the immune system, which may cause immune-related adverse effects. The predictors and mechanisms of anti-PD-1-associated thyroid immune injury remain unclear.

Methods: A retrospective analysis is conducted on 518 patients treated with anti PD-1/PD-L1. Firstly, the differences between anti PD-1 and anti PD-L1 are compared on the risk of thyroid immune injury. Then, the predictors of the risk and thyroid function for anti PD-1 related thyroid immune injury are analyzed. Furthermore, the in vitro mechanism of normal thyroid cells (NTHY) is studied. First, the effect of anti PD-1 on the cell viability and immune sensitivity of thyroid cells is observed. Cell viability includes cell proliferation, Apoptosis, cell cycle, T4 secretion, while immune sensitivity includes molecular expression and CD8 + T cell aggregation and killing towards NTHY. Then the differentially expressed proteins (DEPs) are screened by protein mass spectrometry. Enrichment of KEGG pathway and annotation of GO function on DEPs are conducted. Human protein-protein interactions are obtained from STRING database. The network is constructed and analyzed using Cytoscape software. In vitro, key proteins and their pathways are validated through overexpression plasmids or inhibitors. The recovery experiment and the immuno-coprecipitation experiment are designed to support the results. In vivo, the key proteins are detected in the thyroid tissue of mice fed with anti PD-1, as well as in the thyroid tissue of patients with Hashimoto's thyroiditis.

Results: Thyroid irAE is associated with female, IgG, FT4, TPOAb, TGAb, TSHI, TFQI, and TSH. Peripheral lymphocytes are associated with thyroid function. In vitro, the NIVO group shows prologed G1 phase, decreased FT4, downregulated PD-L1, upregulated IFN-γ, and more CD8 + T cell infiltration and cytotoxicity. AKT1-SKP2 is chosen as the key protein. Akt1 overexpression and SKP2 inhibitor replies to NIVO and Akt1 overexpression, respectively. Immunoprecipitation shows SKP2 and PD-L1 interaction.

Conclusion: Female, impaired thyroid hormone sensitivity and IgG4 contribute to the risk of thyroid irAE, while peripheral blood lymphocyte characteristics affect thyroid function. Anti-PD-1 induces thyroid irAE by downregulating AKT1-SKP2 to enhance thyroid immunosensitivity.

Keywords

AKT1; Anti-PD-1; CD8+T cells; PD-L1; SKP2; Thyroid irAE.

Figures
Products